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Evolution of Multidrug-Resistant Staphylococcus aureus
Infections in Horses and Colonized Personnel
in an Equine Clinic Between 2005 and 2010
Sandra Sieber,1 Vinzenz Gerber,2 Vendula Jandova,2 Alexandra Rossano,1
John Marc Evison,3 and Vincent Perreten1
A total of 70 Staphylococcus aureus isolates from postoperative infections in hospitalized horses were isolated
between January 2005 and January 2011. Among them, 12 isolates were methicillin-susceptible S. aureus (MSSA),
18 were borderline-oxacillin-resistant S. aureus (BORSA), and 40 were methicillin-resistant S. aureus (MRSA).
During the same period, the equine clinic personnel were screened for nasal carriage of BORSA and MRSA.
Genotyping revealed that BORSA ST1(MLST)-t2863(spa) isolates were responsible for most equine infections and
were the main isolates found in colonized members of the personnel between 2005 and 2007, and that in 2007,
MRSA ST398-t011-IVa(SCCmec) emerged in infection sites and personnel, replacing BORSA. Besides decreased
susceptibility to oxacillin, all MRSA and BORSA of these two major clonal lineages displayed resistance to
gentamicin and kanamycin conferred by the aac(6’)-Ie-aph(2’)-Ia gene and to trimethoprim conferred by dfr(K) in
MRSA and dfr(A) in BORSA. All MRSA had additional resistance to tetracycline conferred by tet(M), whereas
BORSA generally also display resistance to streptomycin conferred by str. The number of hospital-acquired
MRSA infections in horses could be limited after the introduction of basic hygiene measures and personnel
decolonization. Two MRSA carriers could not be decolonized using mupirocin, and a year after decolonization,
additional members were recolonized with MRSA. Hygiene measures should, therefore, be maintained to limit
the transmission of S. aureus between personnel and horses.
Introduction
Bacterial infections caused by methicillin-resistantStaphylococcus aureus (MRSA) have increasingly become
problematic in equine clinics.17,31,35,38,42 Specific MRSA be-
longing to clonal complexes CC1, CC5, CC8, CC22, CC59,
CC88, CC398, and mainly to spa type t002, t008, t009, t011,
t020, t022, t032, t034, t036, t064, t127, t166, t186, t216, t451,
t588, t1197, t1451, and t2123 have been identified as a cause of
nosocomial infections in numerous equine clinics.9,27,37–39,43
S. aureus can colonize the skin and mucosa, especially nasal
mucosa, of healthy horses and humans, which then acts as a
reservoir for MRSA and contributes to its spread into the
community and hospitals.14,35,38,40 Horses entering the hos-
pital have been shown to contribute to the introduction and
spread of MRSA in the clinic.38 Once present in the hospital
environment, MRSA may persist and become responsible for
increasing rates of nosocomial infections. Colonized veteri-
nary personnel can potentially transmit MRSA to humans or
to their equine patients and can contaminate materials.4,35,41
MRSA was detected in rooms where veterinary students and
staff member gather.30,38 Hand hygiene is considered to be
one of the most important infection-control tools in human
medicine28 and has also been shown to limit the number of
infections with MRSA in equine clinics.1,31
Bacterial infections of horses have been routinely screened
at the Equine Clinic of Bern, Switzerland.31 From the year
2005, there was an increasing number of S. aureus infections
with borderline-oxacillin-resistant S. aureus (BORSA) and
MRSA.31 BORSA are characterized by decreased suscepti-
bility to oxacillin at a minimum inhibitory concentration
(MIC) of 1–2mg/L, which may result from either over-
expression of the b-lactamase gene blaZ or mutations in
penicillin-binding-proteins PBP1, 2, or 4.7,13,44 Unlike MRSA,
BORSA does not contain an alternative penicillin-binding
protein PBP2a.7 The PBP2a of MRSA is specified by the gene
1Institute of Veterinary Bacteriology, and 2Equine Clinic, Department of Clinical Veterinary Medicine, Vetsuisse Faculty, University of
Bern, Bern, Switzerland.
3University Clinic of Infectious Diseases, University Hospital Bern, Bern, Switzerland.
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mecA, which is situated on a transferable Staphylococcus
Cassette Chromosome mec (SCCmec).10,15 BORSA and MRSA
generally also contain additional antibiotic resistance genes
and display a multidrug-resistance profile.3,10,31
This study describes the evolution of infections with
BORSA and MRSA in horses and nasal carriage among
personnel in the Equine Clinic of Bern during a 6-year
period. The genetic characterization of these multidrug-
resistant S. aureus isolates should determine whether specific
clones were responsible for nosocomial infections and whe-
ther clinic personnel contributed to the introduction and the
spread of these pathogens into the clinic. The results here
also served as a baseline for evaluating newly introduced
adequate hygiene measures and evaluating the effects of
personnel decolonization of MRSA on the control of infec-
tions in the Equine Clinic of Bern.
Materials and Methods
Sample collection
Between January 1, 2005, and January 31, 2011, all horses
(n¼ 686) suffering from a postoperative purulent infection or
thrombophlebitis were sampled with swabs (Oxoid Ltd.,
Basingstoke, Hampshire, England) at the University Equine
Clinic of Bern. Clinical information was obtained from the
Equine Clinic database using OblonData software (Amacker
& Partner Informatik, Zurich, Switzerland). All clinical
samples from horses were taken from ichor. Only the first
sample per patient was considered in the data analysis, and
horses with recurrent infections were not included. The
number of horses that underwent surgery, the number of
postsurgery infections, and the number of samples taken
from infected sites during this period are listed in Table 1.
The prevalence of S. aureus in infected sites was calculated by
dividing the number of infection sites containing S. aureus by
the number of samples taken from ichor. The nasal cavities of
135 horses entering the Equine Clinic over a 3-month period
( January to March 2008) were also tested for BORSA and
MRSA using swabs to estimate carriage on admission.
All the equine clinic personnel, consisting of veterinarians,
anesthesiologists, technicians, and students on clinical rota-
tions, participated spontaneously in the study and were
tested five times between 2006 and 2010 for the presence of
BORSA and MRSA using nasal swabs premoistened in
physiological saline solution (0.85% NaCl) (Table 1). The
variable number of sampled people was due to the rotation
of students and residents. In 2008, staff from the radiology
wards were also included. The prevalence of MRSA and
BORSA carriage in the personnel was calculated by dividing
the number of carriers by the number of persons sampled.
During the follow-up after the decolonization treatment of
the personnel, samples were taken from the nose, throat, and
the inguinal region as previously described 26.
Isolation and identification of staphylococci
Bacteria were cultivated from swabs on trypton-soya-agar
plates containing 5% sheep blood (Becton, Dickinson &
Company, Franklin Lakes, NJ) for 24–48 hr at 378C. S. aureus
isolates were identified by hemolysis, Gram-staining, cata-
lase activity, and using SaSelect chromogenic agar (Bio-Rad
Laboratories AG, Reinach, Switzerland). S. aureus colonies
T
a
b
l
e
1.
O
c
c
u
r
r
e
n
c
e
o
f
S
t
a
p
h
y
l
o
c
o
c
c
u
s
a
u
r
e
u
s
in
In
fe
c
t
e
d
S
it
e
s
o
f
H
o
r
se
s
A
ft
e
r
S
u
r
g
e
r
y
a
n
d
N
a
sa
l
C
a
r
r
ia
g
e
in
P
e
r
so
n
n
e
l
fr
o
m
Ja
n
u
a
r
y
20
05
t
o
Ja
n
u
a
r
y
20
11
P
re
v
al
en
ce
of
S
.
au
re
u
s
in
in
fe
ct
io
n
si
te
s
af
te
r
su
rg
ic
al
p
ro
ce
d
u
re
s
P
re
v
al
en
ce
of
M
D
R
S
.
au
re
u
s
ca
rr
ia
g
e
in
p
er
so
n
n
el
Y
ea
r
N
u
m
be
r
of
h
or
se
s
ad
m
it
te
d
N
u
m
be
r
of
su
rg
ic
al
p
ro
ce
d
u
re
s
N
u
m
be
r
of
h
or
se
s
w
it
h
in
fe
ct
io
n
af
te
r
su
rg
ic
al
p
ro
ce
d
u
re
sa
N
u
m
be
r
of
sa
m
p
le
d
in
fe
ct
io
n
si
te
s
M
S
S
A
M
R
S
A
B
O
R
S
A
A
ll
S
.
au
re
u
s
N
u
m
be
r
of
sa
m
p
le
d
p
eo
p
le
(m
on
th
)
M
R
S
A
B
O
R
S
A
20
05
1,
69
2
34
9
33
(9
.5
%
)
33
0
0
2
(6
.1
%
)
2
(6
.1
%
)
0
N
D
N
D
20
06
1,
70
5
32
1
10
9
(3
3.
4%
)
10
9
2
(1
.8
%
)
1
(0
.9
%
)
10
(9
.2
%
)
13
(1
1.
9%
)
26
(M
ar
ch
)
0
4
(1
5.
4%
)
20
07
1,
70
5
38
4
10
6
(2
7.
6%
)
10
6
5
(4
.7
%
)
10
(9
.4
%
)
6
(5
.7
%
)
21
(1
9.
8%
)
30
(F
eb
ru
ar
y
)
1
(3
.3
%
)
0
28
(A
u
g
u
st
)
6
(2
1.
4%
)
0
20
08
1,
76
7
27
5
74
(2
6.
9%
)
74
2
(2
.7
%
)
8
(1
0.
8%
)
0
10
(1
3.
5%
)
45
b
(J
an
u
ar
y
)
10
(2
2.
2%
)
0
20
09
1,
83
3
33
7
69
(2
0.
5%
)
69
2
(2
.9
%
)
8
(1
1.
2%
)
0
10
(1
4.
5%
)
0
N
D
N
D
20
10
c
1,
71
5
31
8
82
(2
5.
8%
)
82
1
(1
.2
%
)
13
(1
5.
9%
)
0
14
(1
7.
1%
)
33
(J
an
u
ar
y
)
6
(1
8.
2%
)
0
20
05
–2
01
0c
10
,4
17
1,
98
4
68
6
(3
4.
6%
)
68
6
12
(1
.7
%
)
40
(5
.8
%
)
18
(2
.6
%
)
70
(1
0.
2%
)
16
2
23
(1
4.
2%
)
4
(2
.5
%
)
a
In
cl
u
d
e
w
o
u
n
d
in
fe
ct
io
n
s
an
d
th
ro
m
b
o
p
h
le
b
it
is
.
b
In
cl
u
d
e
p
er
so
n
n
el
o
f
th
e
ra
d
io
lo
g
y
w
ar
d
.
c I
n
cl
u
d
e
Ja
n
u
ar
y
20
11
.
N
D
,
n
o
t
d
et
er
m
in
ed
;
B
O
R
S
A
,
b
o
rd
er
li
n
e-
o
x
ac
il
li
n
-r
es
is
ta
n
t
S
ta
p
h
y
lo
co
cc
u
s
au
re
u
s;
M
R
S
A
,
m
et
h
ic
il
li
n
-r
es
is
ta
n
t
S
ta
p
h
y
lo
co
cc
u
s
au
re
u
s;
M
S
S
A
,
m
et
h
ic
il
li
n
-s
u
sc
ep
ti
b
le
S
ta
p
hy
lo
co
cc
u
s
au
re
u
s;
M
D
R
,
m
u
lt
id
ru
g
-r
es
is
ta
n
t.
472 SIEBER ET AL.
were spread onto MRSA selective agar (MRSA II; Becton,
Dickinson & Company). On this agar, BORSA growth was
not inhibited, and small colonies appeared after 24 hr of in-
cubation at 378C. MRSA were confirmed by the detection of
the mecA gene by PCR.34
Antimicrobial susceptibility testing
MICs of antibiotics were determined by broth microdilu-
tion in Mueller-Hinton using custom Sensititre susceptibility
plates, model NLV73 (Trek Diagnostics Systems, East Grin-
stead, England; MCS Diagnostics BV, Swalmen, The Neth-
erlands), and according to CLSI guidelines.5 Antibiotic
resistance genes were detected using a microarray.33
Genotyping
Genomic DNA was isolated using the peqGOLD Bacterial
DNA Isolation Kit (Classic Line, PEQLAB Biotechnologie
GmbH, Erlangen, Germany). Genetic relatedness was de-
termined by multilocus sequence typing (MLST), spa typing,
SCCmec typing, and variable-number-tandem-repeat
(VNTR)-based method. Sequence types (ST) were deter-
mined as previously described 11 and were assigned using
the MLST-Homepage (http://saureus.mlst.net). Spa type was
determined as previously described and analyzed using the
Ridom StaphType software (Ridom StaphType, Ridom
GmbH, Wu¨rzburg, Germany).16 SCCmec types were deter-
mined using different multiplex PCR assays identifying the
ccr gene complex (ccr type), the mec gene complex (mec class),
and the joining regions (subtype).23 VNTR was performed as
previously described.12 The presence of the Panton-Valentine
leukocidin (PVL) gene lukS was determined by PCR as pre-
viously described.25
Decolonization of MRSA-positive humans
Decolonization was performed according to clinical rec-
ommendations of the University Hospital of Bern.26 Mupir-
ocin was applied thrice a day in both nares, a 0.1%
chlorhexidin solution was gargled twice daily to decolonize
the pharynx, and the body and the hair were washed by
showering with 4% chlorhexidin soap once a day. This pro-
cedure was repeated for 5 days. All clothes and bedding were
changed and washed after the shower. Clearance of MRSA
was assumed when two or more swabs were negative during
the final follow-up screenings using a selective culture.26
Hygiene measures at the Equine Clinic
Hygiene measures introduced at the Equine Clinic have
been described in detail by Panchaud et al.31 Briefly, they
consisted of using new gloves and hand disinfection (Ster-
illium; BODE Chemie, Hamburg, Germany) between con-
tact with patients as well as stabling of equine MRSA-carriers
in isolation facilities.
Results
Occurrence and source of S. aureus in horses
A total of 70 clinical isolates of S. aureus from hospitalized
horses were isolated between January 2005 and January 2011.
Among them, 12 isolates were methicillin-susceptible S. aureus
(MSSA) (17.1%), 18 were BORSA (25.7%), and 40 were MRSA
(57.1%) (Fig. 1). Three additional MRSA were isolated from the
nasal cavities of 3 of 135 horses screened on arrival during a
3-month period from January toMarch 2008. These three horses
had already been hospitalized once at the clinic in the previous 6
months and had developed an MRSA infection at that time.
The 18 BORSA were isolated from the infection that de-
veloped after surgical procedures on 15 horses, thrombo-
phlebitis after catheterization on two horses, and from the
nasal discharge of one horse which developed rhinitis after
hospitalization. The 40 MRSA originated from 34 horses that
developed an infection after surgical procedures and from 6
with a thrombophlebitis after catheterization. The 12 MSSA
were isolated from 7 horses that developed postsurgery
wound infections and from 5 with thrombophlebitis. Each
year, the percentage of postsurgical infections caused by
MSSA was always lower (0%–4.7%) than the percentage of
infections caused by multidrug-resistant staphylococci
(BORSA and MRSA) (6.1%–15.9%) (Table 1). Although the
percentage of infections caused by BORSA decreased from
9.2% in 2006 to 0% in 2008, the percentage of infections
caused by MRSA after surgical procedures increased from
0.9% in 2006 to 15.9% in 2010 (Table 1).
Characteristics and occurrence of BORSA and MRSA
Between January 2005 and August 2007, BORSA was re-
sponsible for a significant number of staphylococcal infections
in horses (18/31, 58.1%) (Fig. 1). The majority of the BORSA
isolates (16/18) shared the same VNTR profile and belonged
to ST1 and spa type t2863 (ST1-t2863). The two other BORSA
isolates showed different VNTR profiles as BORSA ST1-t2863
and belonged to the clonal lineages ST1-t127 and to the new
ST1660-t3043 (Table 2). They were only isolated once from
infection sites in horses. All BORSA displayed the same
multidrug-resistance profile with resistance to penicillin
[blaZ], to trimethoprim [dfr(A)], to gentamicin and kanamycin
[aac(6’)-Ie-aph(2’)-Ia], to streptomycin [str], and decreased
susceptibility to oxacillin at an MIC of 1–2mg/L. Only five
BORSA isolates did not contain the streptomycin resistance
gene str including three BORSA ST1-t2863 as well as BORSA
ST1-t127 and ST1660-t3043 (Table 2). During the outbreak
with BORSA, four humans were also found to be carriers of
the BORSA clone ST1-t2863 (Table 2 and Fig. 1).
The first MRSA infection in horses at the Equine Clinic of
the University of Bern occurred in March 2006. This first
MRSA isolate belonged to the clonal lineage ST398-t011-
V(SCCmec), which was only detected at that time (Fig. 1).
This unique MRSA ST398-t011-V isolate also differed from
the other MRSA that has been causing infections since 2007
by the presence of the streptomycin resistance gene ant(6)-Ia,
the macrolide resistance genes msrA and mph(C), and the
tetracycline resistance gene tet(K) (Table 2). Indeed, in Feb-
ruary 2007, MRSA ST398-t011-IVa was detected in the nasal
cavity of one member of the personnel (see below) and be-
came rapidly responsible for most infections in horses caused
by S. aureus. Also, BORSA was not isolated at any time
points after 2007 from infection sites (Fig. 1). Since then, all
MRSA isolates from horses shared the same VNTR-profile
and belonged to the same clonal lineage ST398-t011-IVa,
except one isolated in October 2009 (ST398-t2970-IVa) and
one isolated in January 2011 (ST8-t064-IVd) (Fig. 1 and Table
2). They all displayed resistance to b-lactams conferred by
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mecA and blaZ, to the aminoglycosides gentamicin and
kanamycin [aac(6’)-Ie-aph(2’)-Ia], to trimethoprim [dfr(K)],
and to tetracycline [tet(M)], except one ST398-t011-IVa,
which showed additional resistance to streptomycin [str] and
to macrolides and lincosamides [erm(C)]. This latter isolate
was also present in the nasal cavity of one member of the
personnel. Otherwise, the personnel was predominantly
colonized with MRSA of the former ST398-t011-IVa lineage
(Table 2 and Fig. 1). In October 2010, ciprofloxacin resistance
emerged in one MRSA ST398-t011-IVa strain isolated from
an infected wound of a horse after surgery. Ciprofloxacin-
resistant MRSA ST398-t011-IVa was again isolated from in-
fected sites of horses in November 2010 and January 2011.
Apart from two MRSA isolates that displayed resistance to
erythromycin and three to ciprofloxacin, all MRSA and
BORSA isolates were susceptible to erythromycin and ci-
profloxacin as well as to vancomycin, sulfamethoxazole, ni-
trofurantoin, linezolid, amikacin, chloramphenicol, and the
combination quinupristin-dalfopristin. Neither BORSA nor
MRSA from humans and horses contained the PVL gene.
Evolution of BORSA and MRSA carriage
in the personnel
In 2006, 4 of 26 tested personnel carried BORSA ST1-
t2863, and none carried MRSA. In February 2007, none of
the 30 tested personnel carried BORSA, and 1 carried MRSA
ST398-t011-IVa. In August 2007, 6 of 28 tested personnel
carried MRSA ST398-t011-IVa, and none carried BORSA. In
January 2008, 10 of 45 tested personnel carried MRSA
ST398-t011-IVa (Table 1). One of them belonged to the an-
esthesia ward. In February 2008, MRSA carriers were de-
colonized at the University Hospital of Bern. Two of them
were still positive after the third sampling in May 2008,
when decolonization was stopped. Those two personnel
were among the 6 of 33 tested persons that were MRSA-
positive in 2010. They still harbored MRSA ST398-t011-IVa.
This clonal lineage was also detected in one person who
was previously decolonized and tested negative and in two
people who never tested MRSA-positive earlier. In 2010,
ST8-t064-IVd was detected for the first time among the
personnel in Bern. It was detected in one newly hired per-
son who started work at the clinic at the beginning of 2010.
This newly hired person had worked earlier in a German
horse clinic where this clone has been detected in both
horses and humans39. One year later, MRSA ST8-t064-IVd
was detected for the first time in the infection site of a horse
at the Equine Clinic of Bern (Fig. 1). This MRSA ST8-t064-
IVd isolate contained resistance genes conferring resistance
to beta-lactams [mecA, blaZ], trimethoprim [dfr(A)], genta-
micin and kanamycin [aac(6’)-Ie-aph(2’)-Ia], and tetracycline
[tet(M)].
FIG. 1. Evolution of infections caused by MSSA and multidrug-resistant Staphylococcus aureus (BORSA and MRSA) in
horses after hospitalization and nasal colonization in humans. ~: hospital-acquired MSSA isolate; : BORSA isolate ST1-
t2863; *: BORSA isolate ST1-t127; &: BORSA isolate ST1660-t3043; ^: MRSA isolate ST398-t011-IVa; $: MRSA isolate ST8-
t064-IVd; : MRSA isolate ST398-t011-V;*: MRSA isolate ST398-t2970-IVa; : Hygiene measures; : Decolonization of
humans with mupirocin;?: Relaxation of hygienic measures (gloves and hand disinfection only for horses with wounds);
underlined months: period when nasal samples were collected in personnel; months underlined with dash line: period when
persons who underwent decolonization were tested for the last time during the follow-up screening; cipR, resistance to
ciprofloxacin; t, isolates from thrombophlebitis; BORSA, borderline-oxacillin-resistant Staphylococcus aureus; MRSA, methi-
cillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
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Decolonization of personnel and implementation
of hygienic measures
The decolonization treatment was only applied to the
personnel harboring MRSA. The decolonization of the per-
sonnel was performed 3 months after the introduction of
hygienic precautions in January 2008. During the 6 months
after decolonization, no horses developed an infection
caused by MRSA, although two members of the personnel
could not be decolonized and were still carriers (Fig. 1).
During that time, only two postsurgical infections caused by
MSSA were reported. Consequently, to decrease S. aureus
infections, gloves were only worn for contact with horses
with wounds. This had the unfortunate consequence of
rapidly increasing the number of MRSA infections in horses
in January 2009 (Fig. 1). In June 2009, the implementation of
new glove rules was followed by mandatory hand-disinfec-
tion for each contact with patients as well as the clinic-owned
horses. These measures limited the transmission of MRSA to
horses but not to personnel. Indeed, from July 2009 to Au-
gust 2010, the number of nosocomial infections in horses
caused by MRSA and MSSA was limited to seven and one
cases, respectively, though approximately one-fifth of the
personnel (six people) were MRSA carriers (Fig. 1 and Table
1). From September 2010, laxity and lack of awareness in the
application of hand hygiene were observed, which may be
the cause of a re-increase of the S. aureus infections by the
end of 2010 (Fig. 1).
Discussion
Between 2005 and 2010, two major clones of multidrug-
resistant S. aureus caused nosocomial infections in horses.
BORSA ST1-t2863, which was prevalent in wound infections
until 2007, was rapidly replaced by MRSA ST398-t011-IVa.
During this period, the personnel harbored the same strains
in their nose as the ones causing infections in horses, indi-
cating direct transmission between humans and horses. In-
deed, the number of infections with BORSA in horses
became less frequent once BORSA carriage in humans dis-
appeared. Similarly, the number of infections with MRSA in
horses and nasal carriage in the personnel increased rapidly
after MRSA had been introduced into the Equine Clinic of
Bern. Such a rapid spread of MRSA among the horses and
personnel also happened in the Netherlands after the intro-
duction of MRSA into the clinic.38 In Bern, MRSA ST398-
t011-IVa was first detected among one member of the
personnel; it has never been detected in horses earlier. This
person was previously working in an equine clinic in Bel-
gium, a country where MRSA ST398-t011 is prevalent in the
equine population.18,37 Similarly, ST8-t064-IVd was first de-
tected in 2010 in one newly hired person from a German
Clinic where this clonal lineage has been reported in both
horses and humans39 and it was detected 1 year later in the
infection site of one horse at the Equine Clinic Bern, thus
emphasizing the role of humans in the introduction of MRSA
into equine clinics. During a 6-month period from March to
August 2007, after the introduction of MRSA into the clinic in
Bern, infections in horses were caused by either MRSA or
BORSA. After that, infections were only caused by MRSA;
BORSA disappeared completely from infection sites. MRSA
ST398-t011-IVa may have a better affinity for invasion and
colonization of horses or humans than BORSA ST1-t2863.
The colonization and dissemination potential of S. aureus
ST398-t011 is supported by the fact that this MRSA clone has
also been successfully spreading in a variety of animal
species as well as in humans during the past
years.2,8,19,24,36,38,42,43 Of note, the BORSA and MRSA strains
of our study did not appear to be particularly more virulent
than other S. aureus in horses. Infected equine patients did
not suffer from increased frequency or severity of compli-
cations in wound healing, nor did colonized humans de-
velop clinical signs. MRSA ST398-t011-IVa showed a high
affinity for persistence and colonization and could not be
eliminated from the nasal cavities of two members of the
personnel using decolonization treatment. One year after
decolonization, five people were MRSA carriers of the same
MRSA clone ST398-t011-IVa, and one newly hired person
carried MRSA ST8-t064-IVd. Thus, MRSA decolonization of
equine clinic personnel is not very successful as long as the
personnel areworking in a clinical environment. This could be
due to possible failures of the decolonization or to the pres-
ence of many risk factor such as antibiotic selective pressure
and the spread of MRSA between horses and personnel.26,38
Additionally, repeated decolonization with mupirocin may
select for a mupirocin-resistant MRSA-population.32 Persis-
tent staphylococci carriage and intermittent staphylococci
colonization in humans is well described and occurs in about
30% and 60% of the population, respectively.21 Intermittently,
colonized people are colonized with different S. aureus strains
at varying frequencies.21
The use of antibiotics and the subsequent environmental
contamination with antibiotics such as penicillin is an im-
portant risk factor for nasal colonization and transmission of
antibiotic resistant bacteria to patients.21,22,29 Penicillin has
been routinely used at the Equine Clinic of Bern for the
prevention of infections before and after surgery, and the use
of this antibiotic has been shown to select for specific mul-
tidrug-resistant staphylococcal flora including BORSA.34 To
prevent the spread of multidrug-resistant S. aureus in the
clinic, prophylactic use of penicillin has been limited and
hygienic measures, including the changing of gloves be-
tween patients and the use of hand disinfectants, have been
introduced. Horses infected with MRSA are isolated in spe-
cial isolation stalls.31 Additionally, horses with a history of
MRSA infection are currently directly isolated in case of
hospitalization, because they have been shown to possibly
still carry MRSA in their nasal cavity. The continuous ap-
plication of these measures is necessary to limit the number
of postsurgical wound infections and thrombophlebitis in
horses caused by nosocomial multidrug-resistant S. aureus.
Relaxation of hand hygiene measures led to a rapid increase
in the number of MRSA infections in horses. Additionally,
fluoroquinolones that have been used for the treatment of
MRSA infections have likely selected for fluoroquinolone-
resistant MRSA ST398-t011-IVa isolates. Therapeutic strate-
gies also need to be established to limit the selection and the
spread of such isolates.
This study showed that the livestock-associated MRSA
ST398-t011 recently emerged in horses in Switzerland, pre-
sumably introduced into the clinic through the personnel. It
rapidly replaced another multidrug-resistant S. aureus,
BORSA, which had been previously responsible for nosoco-
mial infections at the Equine Clinic of Bern. Concurrent
colonization of personnel with MRSA isolates indistin-
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guishable from those recovered from horses has also been
reported in other clinics.35,38,41 Our study supports the no-
tion that humans play a role in the introduction and trans-
mission of multidrug-resistant S. aureus within a clinic. It is,
therefore, necessary to stop the transmission between per-
sonnel and patients using gloves and hand disinfectants, as
hands are considered a major transmission vehicle for
MRSA.20,28 Prevention of nasal carriage in humans needs to
be addressed, as nasal decolonization was not successful as
long as people were working in a clinical environment.
Long-term surveillance as well as continuous and strict hy-
giene measures should be maintained to prevent the spread
of nosocomial bacteria. Preventing nosocomial MRSA infec-
tions represents a new challenge to equine clinics requiring
improved hygiene awareness among all personnel, begin-
ning with strict hand sanitation.
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